Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-048: progression post next line for R/M HNSCC

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, discusses data from the KEYNOTE-048 study (NCT02358031) which evaluated progression after the next line of therapy following pembrolizumab or pembrolizumab plus chemotherapy vs the EXTREME regimen as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).